[HTML] sciencedirect.com

[HTML][HTML] Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma

IT Chiang, YH Lee, ZL Tan, FT Hsu, HF Tu - Biomedicine & …, 2022 - Elsevier
Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …
被引用次数：16 相关文章

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma

IT Chiang, YH Lee, ZL Tan, FT Hsu… - Biomedicine and …, 2022 - scholar.nycu.edu.tw
Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.

IT Chiang, YH Lee, ZL Tan, FT Hsu… - Biomedicine & …, 2022 - europepmc.org
Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma

IT Chiang, YH Lee, ZL Tan… - Biomedicine and …, 2022 - mdanderson.elsevierpure.com
Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma

IT Chiang, YH Lee, ZL Tan… - Biomedicine & …, 2022 - pubmed.ncbi.nlm.nih.gov
Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …